Estradiol valerate 2mg / Levonorgestrel 75microgram tablets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
Part of the FemSeven brand family (generic: Estradiol + Levonorgestrel)
MHRA licensed products
View all licensed products for Estradiol + Levonorgestrel on the MHRA register
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Heavy menstrual bleeding: assessment and management (NG88)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 18 · 1980–2026
Showing the 50 most relevant studies, sorted by most relevant.
Hans-Joachim Ahrendt, Dagmar Makalová, Susanne Parke, et al.
Contraception, 2009
- Contraceptives, Oral, Combined
- Drug Combinations
- Estradiol
Diane Thiboutot, David F. Archer, André Lemay, et al.
Fertility and Sterility, 2001
Lin Chen
American Journal of Internal Medicine, 2016
Glynne S, Kamal A, McColl L, et al.
2026
- Testosterone
- Estradiol
- Depression
BackgroundPsychological symptoms in perimenopause and early menopause are common. The impact of menopausal hormone therapy (MHT) on menopausal mood symptoms is unclear.AimsTo assess the impact of 17β-oestradiol ± micronised progesterone or the levonorgestrel-releasing intrauterine device, and/or transdermal testosterone, on depressive and anxiety symptoms in peri- and postmenopausal women.MethodA real-world retrospective cohort study set in the largest specialist menopause clinic in the UK. The Meno-D questionnaire measured mood-related symptoms.ResultsThe study included 920 women: 448 (48.7%) perimenopausal, and 435 (47.3%) postmenopausal. Following initiation/optimisation of MHT, mean Meno-D scores decreased by 44.59% (95% CI -46.83% to -42.34%, P P v. 48.53%, respectively, P = 0.47) and MHT optimisation strategy (MHT users treated with a higher oestradiol dose versus testosterone added versus both a higher oestradiol dose and testosterone, 34.70, 43.93 and 43.25%, respectively, P = 0.38).ConclusionsUse of menopausal hormone therapy was associated with significant improvement in mood in peri- and postmenopausal women. Prospective studies and randomised clinical trials are needed to assess the effects of different regimens in different patient populations over longer time periods.
Abstract licence: CC BY
Zhang YJ, Wang XD, Shan M, et al.
2026
- Polyps
- Levonorgestrel
- Ethinyl Estradiol
James Leyden, Alan R. Shalita, Maria Hordinsky, et al.
Journal of the American Academy of Dermatology, 2002
- Acne Vulgaris
- Contraceptives, Oral, Synthetic
- Drug Combinations
Marta Durand, Marı́a del Carmen Cravioto, Elizabeth G. Raymond, et al.
Contraception, 2001
- Biopsy
- Contraceptive Agents
- Contraceptives, Postcoital
A. Teíchmann, Dan Apter, Janusz Emerich, et al.
Contraception, 2009
- Metrorrhagia
- Contraceptives, Oral, Combined
- Ethinyl Estradiol
R. Ryan, Aamirah Mussa, Mandisa Singtaa-Madliki, et al.
Frontiers in Global Women's Health, 2022
Santa Maria, Heriyadi Manan, Adenan Abadi, et al.
Indonesian Journal of Obstetrics and Gynecology, 2020
Abstract Objective: To find out the comparison of the effect of one-rod and two-rod levonorgestrel implants on FSH, estradiol levels and increase in acceptor lipid profile after a 3-month evaluation in the Mother Hospital of Rika Amelia Palembang.Methods: This study was a phase III clinical trial, "Open" (Open Randomized Clinical Trial), carried out randomization by comparing two types of implant KB, namely levonorgestrel implants, one rod with two rods. This research was conducted at the RSAB Rika Amelia Palembang. Research time is 6 months from November 2018 - April 2019 or until the number of samples is fulfilled.Results: Based on the installation time, the average installation time using one rods LNG was 1.54 ± 0.11 minutes and the LNG for the two rods was 2.49 ± 0.26 minutes. Majority of patients having a normal blood pressure of 89.5% in one rod LNG and 68.4% in two rod LNG. The mean body mass index (BMI) of respondents using LNG implants one rod was 24.19 ± 3.93 kg / m2 and LNG for two rods was 25.09 ± 6.11 kg / m2. Based on the menstrual pattern, it was found that 84.2% of the subjects had regular menstrual patterns in the one-rod LNG group, while there were 63.2 % of subjects who have irregular menstrual patterns. From the statistical test, it was found that there were no differences in cholesterol levels (p = 0.919), HDL (p = 0.793), LDL (p = 0.851) and triglycerides (p = 0.679). There were no differences in FSH levels between respondents using one rod and two rod LNG implants (p = 0.849) and also on estradiol (p = 0.099)Conclusion: There is no difference between the use of one-rod and two-rodlevonorgestrel implants against FSH, Estradiol levels and increased lipid profile after 3 months of implant installation. The unpleasant effect in this study was the decline in HDL, but this was accompanied by a decrease in body weight, total cholesterol, LDL, HDL due to a decrease in all aspects.Keyword: estradiol, FSH, implant contraception, lenovorgestrel, lipid profile, one-rod, two-rod Abstrak Tujuan:Untuk mengetahui perbandingan efek implanlevonorgestrel satu-batang dan dua-batang pada FSH, kadar estradiol dan peningkatan profil lipid akseptor setelah evaluasi 3 bulan di Rumah Sakit Ibu Rika Amelia Palembang.Metode: Penelitian ini adalah uji klinis fase III, "Open" (Open Randomized Clinical Trial), yang dilakukan secara acak dengan membandingkan dua jenis KB implan, yaitu levonorgestrel implan, satu batang dengan dua batang. Penelitian ini dilakukan di RSAB Rika Amelia Palembang. Waktu penelitian adalah 6 bulan dari November 2018 - April 2019 atau hingga jumlah sampel terpenuhi.Hasil :Berdasarkan waktu pemasangan didapatkan rerata waktu pemasangan yang menggunakan LNG satubatangadalah 1,54±0,11 menitdanpada LNG dua batang adalah 2,49±0,26 menit. Mayoritas pasien memiliki tekanan darah yang normal 89.5% pada LNG satu batang dan 68.4% pada LNG dua batang. Rerata indeks massa tubuh (IMT) responden yang menggunakan implan LNG satu batang sebesar 24,19 ± 3,93 kg/m2 dan LNG dua batang sebesar 25,09 ± 6,11 kg/m2. Berdasarkan pola haid, didapatkan sebanyak 84,2% subjek yang memiliki pola haid teratur pada kelompok LNG satu batang, sedangkan terdapat sebanyak 63,2% subjek yang memiliki pola haid tidak teratur. Dari uji statistik didapatkan bahwa tidak terdapat perbedaan kadar kolesterol (p = 0,919), HDL (p = 0,793), LDL (p = 0,851) dan trigliserida (p = 0,679). Tidak terdapat perbedaan kadar FSH antara responden yang menggunakan implan LNG satu batang dan dua batang (p = 0,849) dan juga pada estradiol (p=0.099)Kesimpulan: Tidak terdapat perbedaan antara penggunaan implan levonorgestrel satu batang dan dua batang terhadap kadar FSH, Estradiol serta peningkatan profil lipid setelah 3 bulan pemasangan implan. Efek yang tidak menyenangkan dalam penelitian ini adalah terjaidnya penurunan HDL, namun hal ini disertai dengan penurunan berat badan, kolesterol total, LDL, HDL dikarenakan terjadi penurunan pada seluruh aspek.Kata Kunci: dua batang, estradiol, FSH, kontrasepsi implan, lenovorgestrel, profil lipid, satu batang.
Abstract licence: CC BY-NC-SA 4.0
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.